Monograph

C01CE02 - Milrinone

Propably not porphyrinogenic

PNP

Rationale

Probably no significant CYP-dependent metabolism. Hydrophilic substance, no data pointing to CYP-affinity.

Chemical description

Bipyridine derivative lactate.

Therapeutic characteristics

Used in acute heart failure. Administered as infusion about 1 mg/kgBW/24 h.

Metabolism and pharmacokinetics

Elimination occurs mainly via the urine; about 83% of a dose is excreted as unchanged drug, about 10% as O-glucuronide. Major metabolic pathways appear to be both oxidative and conjugative (primarily glucuronidation), based on animal studies. Some CYP450-mediated metabolism can therefore not be excluded. No data pointing to CYP-interaction.

Preclinical data

None

Personal communication

None

Published experience

None

Similar drugs

Explore alternative drugs in similar therapeutic classes C01C / C01CE or go back.

Tradenames

This list comprises raw data collected from different countries. In some cases, a more comprehensive list of available drug packages is included. Consequently, very similar terms may therefore appear multiple times. Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.

Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors. We strive to improve it continuously.

Show more details and information about the listed tradenames